window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 13, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Phase 1 clinical trial

  • Advanced Therapies,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Oncoinvent publishes Radspherin dosimetry data in Journal of Nuclear Medicine

    Oncoinvent has published Phase 1 dosimetry data for Radspherin in [...]

    August 12, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics

    Ananda Pharma Phase 1 study of MRX1 shows safety and supports Phase 2 progression

    Ananda Pharma has reported positive results from its Phase 1 [...]

    June 18, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Evogene and Shanghai Lishan Biopharmaceuticals enter exclusive licensing agreement for BMC128

    Evogene Ltd and Shanghai Lishan Biopharmaceuticals Co. have entered into [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Evogene licenses microbiome cancer therapy BMC128 to Shanghai Lishan Biopharmaceuticals

    Evogene and Shanghai Lishan Biopharmaceuticals have entered into an exclusive [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    NeoVac reports Phase 1 and Phase 2 data for NeomiVac mRNA LNP covid-19 vaccine

    NeoVac has reported positive first-in-human Phase 1 and Phase 2 [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Skyhawk Therapeutics reports positive nine-month interim results for SKY-0515 in Huntington’s disease

    Skyhawk Therapeutics has reported positive nine-month interim results from its [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    AAVantgarde completes enrollment in LUCE-1 Phase 1 and Phase 2 trial of gene therapy AAVB-081 for Usher syndrome type 1B

    AAVantgarde Bio has completed enrollment in LUCE-1, a first-in-human Phase [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    FoRx Therapeutics starts first-in-human trial of novel PARG inhibitor FORX-428 in advanced solid tumors

    FoRx Therapeutics has initiated a first-in-human clinical trial of FORX-428, [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Oncoinvent publishes Radspherin dosimetry data in Journal of Nuclear Medicine
    Categories: Advanced Therapies, Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Alamar expands Alzheimer’s proteomics partnership with 86,000 more samples
    Categories: Central Nervous System, Genomics and sequencing, Research & Development, Therapeutic Areas
  • OSF HealthCare expands RapidAI clinical AI platform to all 18 hospitals
    Categories: Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Digital & Data, Medical devices
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top